These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33539683)

  • 1. Improving risk-stratification of natalizumab-associated PML.
    Tugemann B; Berger JR
    Ann Clin Transl Neurol; 2021 Mar; 8(3):696-703. PubMed ID: 33539683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
    Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
    Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
    Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations for characterizing the risk of PML in natalizumab-treated patients.
    Koendgen H; Ho PR; Chang I
    Mult Scler Relat Disord; 2016 Sep; 9():121. PubMed ID: 27645357
    [No Abstract]   [Full Text] [Related]  

  • 7. JCV serology in time: 3 years of follow-up.
    Cambron M; Hadhoum N; Duhin E; Lacour A; Chouraki A; Vermersch P
    Acta Neurol Scand; 2017 Jul; 136(1):54-58. PubMed ID: 27766611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A
    Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
    Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K; Gold R
    Nat Rev Neurol; 2017 Dec; 13(12):710-712. PubMed ID: 29146954
    [No Abstract]   [Full Text] [Related]  

  • 11. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A; van Rossum JA; Leurs C; Wattjes MP; Rispens T; Murk JL; Uitdehaag BM; Killestein J
    Eur J Neurol; 2016 Jun; 23(6):1079-85. PubMed ID: 27018481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
    Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.
    Warnke C; Wijburg MT; Hartung HP; Killestein J; Adams O; Wattjes MP
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1092-1094. PubMed ID: 28490505
    [No Abstract]   [Full Text] [Related]  

  • 15. Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
    Hay M; Leguy S; Cahagne V; Lassalle N; Le Page E; Michel L
    Rev Neurol (Paris); 2024 Jun; 180(6):565-567. PubMed ID: 38429158
    [No Abstract]   [Full Text] [Related]  

  • 16. Natalizumab: risk stratification of individual patients with multiple sclerosis.
    Tur C; Montalban X
    CNS Drugs; 2014 Jul; 28(7):641-8. PubMed ID: 24942634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
    van Kempen ZLE; Leurs CE; de Vries A; Vennegoor A; Rispens T; Wattjes MP; Killestein J
    Eur J Neurol; 2017 Sep; 24(9):1196-1199. PubMed ID: 28707781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
    Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
    Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-JC virus antibody titres increase over time with natalizumab treatment.
    Raffel J; Gafson AR; Malik O; Nicholas R
    Mult Scler; 2015 Dec; 21(14):1833-8. PubMed ID: 26449743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.